In his first interview about his book “Ghosts in the Blood,” world-renowned hematologist/oncologist and CLL researcher Jeff Sharman, MD, takes us on a fascinating journey through the history…
When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
In his first interview about his book “Ghosts in the Blood,” world-renowned hematologist/oncologist and CLL researcher Jeff Sharman, MD, takes us on a fascinating journey through the history…
When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
Chromosomes, FISH, and Why Cytogenetics Matter in CLL This episode explains how chromosome analysis helps predict prognosis in chronic lymphocytic leukemia, starting with the basics of how chromosomes…
Join us for an informative webinar featuring Dr. Jennifer Woyach as she provides an overview of the current CLL treatment landscape and the many options available to patients…
